STRO - Sutro Biopharma, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
10.37
-0.32 (-2.99%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close10.69
Open10.58
Bid7.59 x 1800
Ask25.00 x 800
Day's Range10.10 - 11.26
52 Week Range8.50 - 15.90
Volume24,454
Avg. Volume22,698
Market Cap237.736M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-6.13
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.33
Trade prices are not sourced from all markets
  • How free-flowing cash is accelerating small companies' cancer drug trials
    American City Business Journals11 days ago

    How free-flowing cash is accelerating small companies' cancer drug trials

    An unprecedented biotech investment boom means smaller companies can accelerate early-stage drug trials and, potentially, carry them to more patients faster.

  • PR Newswire15 days ago

    Sutro Biopharma to Present at the 18th Annual Needham Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., April 4, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO) today announced that Bill Newell, Chief Executive Officer, will present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9 at 4:50 p.m. ET at the Westin Grand Central Hotel in New York. Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.

  • PR Newswire18 days ago

    Sutro Biopharma Reports Full Year 2018 Financial Results and Recent Business Highlights and Developments

    STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data Expected Mid-2019 STRO-002 Phase 1 Clinical Trial Initiated in Ovarian and Endometrial Cancers SOUTH SAN FRANCISCO, Calif. ...

  • PR Newswirelast month

    Sutro Biopharma Initiates Phase I Clinical Trial of STRO-002 for the Treatment of Ovarian and Endometrial Cancers

    SOUTH SAN FRANCISCO, Calif., March 15, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO) today announced that it has dosed the first patient in a Phase I study of STRO-002, an anti-folate receptor alpha (FoIRα) antibody-drug conjugate (ADC), in patients with ovarian and endometrial cancers. This is the second product candidate to be evaluated in clinical trials resulting from Sutro's XpressCF+™ technology platform.

  • PR Newswirelast month

    Sutro Biopharma to Present at the Cowen and Company 39th Annual Health Care Conference

    SOUTH SAN FRANCISCO, Calif., March 5, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO) today announced that Bill Newell, Chief Executive Officer, will present at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11 at 2:50 p.m. ET at the Marriott Copley Place in Boston. Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company.

  • PR Newswire3 months ago

    Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry

    SOUTH SAN FRANCISCO, Calif., Jan. 29, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO) today announced the appointment of Andreas Maderna, Ph.D., as vice president of chemistry. Dr. Maderna has extensive experience building successful scientific teams and a strong background in medicinal chemistry. "Dr. Maderna arrives at an important time for the company as we continue to fortify our leadership team and advance our cancer therapy pipeline," said Sutro CEO Bill Newell.

  • PR Newswire3 months ago

    Sutro to Present at 37th Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 3, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO) today announced that Bill Newell, Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, Jan. 10, 2019 at 11:30 a.m. PT / 2:30 p.m. ET at the Westin St. Francis Hotel in San Francisco. Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.

  • DAFNA Capital Management Return, AUM and Holdings
    Insider Monkey4 months ago

    DAFNA Capital Management Return, AUM and Holdings

    DAFNA Capital Management, LLC is a Los Angeles-based hedge fund launched by Dr. Nathan Fischel, back in 1999. Dr. Fischel is an experienced Pediatric Hematologist-Oncologist, who graduated from the Technion School of Medicine in Israel and completed his residency at the Children’s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston. For his post-graduate studies […]

  • PR Newswire4 months ago

    Sutro Achieves $10 Million Milestone Payment from Celgene

    SOUTH SAN FRANCISCO, Calif., Dec. 19, 2018 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO), today announced that the company earned $10 million in a milestone payment from Celgene triggered by the successful development of a dry powder XtractCFTM formulation, using spray drying technology, which is well established in the pharmaceutical industry. Dried XtractCFTM is a significant advancement, facilitating the commercial-scale manufacturing of protein therapeutics, using Sutro's proprietary cell-free XpressCFTM technology for its fully owned and partnered programs.

  • This year's Bay Area IPO batch remains up 44% despite market turbulence
    American City Business Journals4 months ago

    This year's Bay Area IPO batch remains up 44% despite market turbulence

    Stocks from eight of the 34 companies from the region that went public this year are now below their IPO price. Six others are trading at double or more where they started.

  • PR Newswire5 months ago

    Sutro to Participate in the 30th Annual Piper Jaffray Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 26, 2018 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics will present at the 30th Annual Piper Jaffray Healthcare Conference.

  • PR Newswire5 months ago

    Sutro Biopharma Reports Third Quarter 2018 Financial Results

    -- STRO-001 Received Orphan Drug Designation for Treatment of Multiple Myeloma -- STRO-002 to Begin Phase 1 Trial for Patients with Ovarian and Endometrial Cancers in Early 2019 SOUTH SAN FRANCISCO, Calif. ...

  • PR Newswire5 months ago

    Sutro Announces IND Submission and Conclusion of 30-Day Review Period for STRO-002, an Antibody-Drug Conjugate (ADC) Targeting Anti-Folate Receptor-α for Treatment of Ovarian and Endometrial Cancer

    - Initiation of Phase 1 Trial Planned for Early 2019 - Company's Second Cell-Free ADC Addressing Unmet Medical Need in Oncology SOUTH SAN FRANCISCO, Calif. , Nov. 13, 2018 /PRNewswire/ -- Sutro Biopharma, ...

  • PR Newswire5 months ago

    Sutro Appoints Industry Veteran Shalini Sharp to Board of Directors

    SAN FRANCISCO, Nov. 8, 2018 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO), today announced that Shalini Sharp, Chief Financial Officer and Executive Vice President of Ultragenyx Pharmaceutical Inc., has been appointed to Sutro's Board of Directors. As a new member of Sutro's board, Ms. Sharp brings over 20 years of experience in the life sciences industry covering strategic financial planning, corporate and business development, risk analysis and investor relations. Ms. Sharp has been Chief Financial Officer at Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on rare genetic disease treatments since 2012, where she leads the company's corporate finance, information technology, and strategy functions.

  • PR Newswire6 months ago

    Sutro's STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma

    SOUTH SAN FRANCISCO, Oct. 12, 2018 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO), has been granted Orphan Drug Designation by the United States Food and Drug Administration (FDA) for STRO-001 for the treatment of multiple myeloma. STRO-001 is a potential first-in-class antibody drug conjugate (ADC) targeting CD74, a protein highly expressed in B-cell malignancies such as multiple myeloma. "There is a growing need for new treatment options for patients with multiple myeloma," commented Bill Newell, Sutro's Chief Executive Officer.

  • 24 Bay Area companies have gone public so far this year. Here's how they've done.
    American City Business Journals7 months ago

    24 Bay Area companies have gone public so far this year. Here's how they've done.

    The flood of local IPOs passed last year's total of 15 in July and appears well on its way to top the recent high 34 in 2014, with four more coming this week. Here's how the stocks from this year's crop of new Bay Area public companies have performed so far.

  • PR Newswire7 months ago

    Sutro Biopharma Announces $85.0 Million Initial Public Offering

    SOUTH SAN FRANCISCO, Calif. , Sept. 26, 2018 /PRNewswire/ -- Sutro Biopharma, Inc., a clinical stage drug discovery, development and manufacturing company focused on leveraging its proprietary integrated ...

  • Benzinga7 months ago

    The IPO Outlook For The Week: Smart Appliances, A Language App and Drugmakers

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Viomi Technology Co., Ltd ( VIOT ) will issue 11.4 million shares between $9 and $11 Tuesday on the Nasdaq. Headquartered ...